GIBF

Silexion Therapeutics is a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers. Its lead product candidate SIL-204 is a locally administered small interfering RNA therapy in an extended-release formulation intended as a first-line treatment for locally advanced pancreatic cancer, typically in combination with standard-of-care chemotherapy. The company concentrates on pancreatic tumors bearing KRAS mutations such as G12D and G12V.

BioVersys is a biopharmaceutical company based in Basel, Switzerland. It specializes in developing new drugs to combat multidrug-resistant bacterial infections by targeting and inhibiting resistance mechanisms using its proprietary TRIC technology platform.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Kamari Pharma specializes in developing innovative treatments for unmet needs and rare diseases within the field of dermatology.

CoreBone develops a bioactive, 100% mineral bone graft material for dental, orthopedic, and spine procedures. The graft is created by embedding bioactive minerals into coral skeletons during their growth, producing a strong, porous material with predictable resorption not derived from human or animal bone. It is designed to accelerate healing and improve bone connectivity by offering a natural alternative to conventional grafts and reducing risks associated with human or animal bone. The company holds patents and know-how related to growing coral for medical applications.

Alpha Omega is a global company dedicated to improving patient care in neurology and neurosurgery through innovative medical devices. Its flagship product is a microelectrode recording system designed to enhance the precision of deep brain stimulation electrode implantation, thereby advancing functional neurosurgery and research.